HYDERABAD, India and PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr.
Oct. 5, 2005 — The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in July to advise that efalizumab therapy may cause immune-related hemolytic anemia, serious infection, ...
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial Patients were randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback